Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs has provided an updated notification on its on-market share buy-back program for its fully paid ordinary shares. The company reported that, as of the latest daily update, it had repurchased a cumulative total of 4,829,786 shares prior to the previous trading day and bought back an additional 100,982 shares on the previous day.
The announcement, dated 27 February 2026, forms part of an ongoing buy-back that began in October 2025 and is being reported to the ASX through daily amendments. This continued execution of the buy-back signals ongoing capital management activity, potentially supporting earnings per share and indicating confidence in the company’s valuation for existing shareholders.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-based provider of pathology and diagnostic laboratory services. Its core business revolves around processing medical tests and analyses for healthcare providers and patients, operating within the healthcare diagnostics industry and serving the domestic Australian market through its network of clinical laboratories.
Average Trading Volume: 706,164
Technical Sentiment Signal: Sell
Current Market Cap: A$417.1M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.